Investigational drug · Phase 3
HTD1801
Also called: Berberine Ursodeoxycholate
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
0 still active
All registered trials
12
Any phase or sponsor naming "HTD1801"
First trial start
2022
Dec 27, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HTD1801", any sponsor or status.
Conditions studied
As listed on its trial records.
- T2DM (Type 2 Diabetes Mellitus)
- Nonalcoholic Steatohepatitis (NASH)
- Type 2 Diabetes
- Type 2 Diabetes Mellitus
Approved drugs for the same conditions: Type 2 diabetes · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HTD1801" as an intervention, largest first.
- Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With MetforminPivotal-lookingCompleted
Shenzhen HighTide Biopharmaceutical Ltd.Industry
NCT06353347 · 551 participants · Start Nov 13, 2023 · Primary completion Dec 12, 2024
Drug: HTD1801; Placebo · For: Type 2 Diabetes Mellitus
Sites: Baotou, China; Beijing, China; Changchun, China · 64 sites in all
- Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 DiabetesPivotal-lookingCompleted
Shenzhen HighTide Biopharmaceutical Ltd.Industry
NCT06350890 · 408 participants · Start Nov 5, 2023 · Primary completion Dec 12, 2024
Drug: HTD1801; Placebo · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Xuancheng, China; Beijing, China; Chongqing, China · 56 sites in all
- Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With MetforminPivotal-lookingCompleted
Shenzhen HighTide Biopharmaceutical Ltd.Industry
NCT06415773 · 367 participants · Start Jun 4, 2024 · Primary completion Jun 13, 2025
Drug: HTD1801; Dapagliflozin · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Beijing, China; Binzhou, China; Changchun, China · 53 sites in all
- HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-DiabetesPivotal-lookingCompleted
HighTide Therapeutics (Hong Kong) LimitedIndustry
NCT05623189 · 218 participants · Start Dec 27, 2022 · Primary completion Mar 31, 2025
Drug: HTD1801; Placebo · For: Nonalcoholic Steatohepatitis (NASH); Type 2 Diabetes
Sites: Chandler, Arizona; Peoria, Arizona; Tucson, Arizona · 45 sites in all
- A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and ExercisePivotal-lookingCompleted
Shenzhen HighTide Biopharmaceutical Ltd.Industry
NCT06411275 · 113 participants · Start Mar 31, 2022 · Primary completion Jan 17, 2023
Drug: HTD1801; Placebo and 1 more · For: Type 2 Diabetes Mellitus
Sites: Beijing, China; Changchun, China; Changde, China · 14 sites in all
- A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)Pivotal-lookingCompleted
HighTide Therapeutics (Hong Kong) LimitedIndustry
NCT03656744 · 101 participants · Start Nov 26, 2018 · Primary completion Feb 7, 2020
Drug: HTD1801; Placebo · For: Fatty Liver, Nonalcoholic; NAFLD; Nonalcoholic Fatty Liver Disease and 3 more
Sites: Chandler, Arizona; Tucson, Arizona; Panorama City, California · 17 sites in all
Institute of Medicinal Biotechnology, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07496177 · 75 participants (planned) · Start Jul 9, 2026 · Primary completion May 31, 2027
Drug: HTD1801 · For: T2DM; CKD
Sites: Weifang, China
HighTide Therapeutics (Hong Kong) LimitedIndustry
NCT03333928 · 59 participants · Start Feb 9, 2018 · Primary completion Apr 30, 2020
Drug: HTD1801; Placebo · For: Primary Sclerosing Cholangitis (PSC)
Sites: Chandler, Arizona; Tuscon, Arizona; Fresno, California · 26 sites in all
HighTide Therapeutics (Hong Kong) LimitedIndustry
NCT03381287 · 50 participants · Start Apr 13, 2018 · Primary completion Dec 31, 2018
Drug: HTD1801 Tablets, 500 mg; HTD1801 Tablets, 1000 mg and 4 more · For: Hypercholesterolemia
Sites: Herston, Australia; Adelaide, Australia; Nedlands, Australia
HighTide Therapeutics (Hong Kong) LimitedIndustry
NCT03099603 · 32 participants · Start Mar 24, 2017 · Primary completion Jul 11, 2017
Drug: HTD1801 · For: Primary Sclerosing Cholangitis
Sites: Melbourne, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Berberine as a Mitochondrial Metabolic Reprogrammer in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Adaptive Energetic Stress, Quality Control, and Translational Limitations.
Rafiei H, Omidian K, Tolentino M, et al. · Nutrients 2026
- Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease: A Narrative Review.
Kim B, Kim J, Kim G, et al. · Pharmaceuticals (Basel) 2026
- A Randomized Placebo-Controlled Trial of HTD1801 Monotherapy in Participants With Type 2 Diabetes.
Ji L, Ma J, Cheng Z, et al. · Diabetes Care 2026
- Analysis of drug development risks for metabolic dysfunction-associated steatotic liver disease from a sustainable accounting perspective.
Liu X, Mirza M · Cost Eff Resour Alloc 2026
- Berberine-Ursodeoxycholate - Bringing Traditional Chinese Medicine to Our World.
Ngo B, Rendell M · NEJM Evid 2026
- HTD1801 in Combination with Metformin for Type 2 Diabetes.
Ji L, Cheng Z, Ma J, et al. · NEJM Evid 2026
Also in development for T2DM (Type 2 Diabetes Mellitus)
- ASC30 A1ASC30Phase 35 trials
Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight
- RAY1225Phase 35 trials
Guangdong Raynovent Biotech Co., Ltd · Obesity, T2DM, T2DM (Type 2 Diabetes Mellitus)
- DWP16001Phase 32 trials
Daewoong Pharmaceutical Co. LTD. · Type 2 Diabetic Nephropathy, T2DM (Type 2 Diabetes Mellitus)
- DWC202518Phase 31 trial
Daewoong Pharmaceutical Co. LTD. · T2DM (Type 2 Diabetes Mellitus)
- SYH2069group 1, group 2Phase 22 trials
CSPC Ouyi Pharmaceutical Co., Ltd. · T2DM (Type 2 Diabetes Mellitus), Overweight or Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.